These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 12200385)

  • 1. Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma.
    Abe M; Hiura K; Wilde J; Moriyama K; Hashimoto T; Ozaki S; Wakatsuki S; Kosaka M; Kido S; Inoue D; Matsumoto T
    Blood; 2002 Sep; 100(6):2195-202. PubMed ID: 12200385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease.
    Oyajobi BO; Franchin G; Williams PJ; Pulkrabek D; Gupta A; Munoz S; Grubbs B; Zhao M; Chen D; Sherry B; Mundy GR
    Blood; 2003 Jul; 102(1):311-9. PubMed ID: 12649140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New insights in myeloma-induced osteolysis.
    Barillé-Nion S; Bataille R
    Leuk Lymphoma; 2003 Sep; 44(9):1463-7. PubMed ID: 14565645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand (RANKL).
    Giuliani N; Colla S; Rizzoli V
    Exp Hematol; 2004 Aug; 32(8):685-91. PubMed ID: 15308315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand.
    Han JH; Choi SJ; Kurihara N; Koide M; Oba Y; Roodman GD
    Blood; 2001 Jun; 97(11):3349-53. PubMed ID: 11369623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Receptor activator of NF-kappaB ligand, macrophage inflammatory protein-1alpha, and the proteasome: novel therapeutic targets in myeloma.
    Oyajobi BO; Mundy GR
    Cancer; 2003 Feb; 97(3 Suppl):813-7. PubMed ID: 12548580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update on the pathogenesis of osteolysis in multiple myeloma patients.
    Giuliani N; Colla S; Rizzoli V
    Acta Biomed; 2004 Dec; 75(3):143-52. PubMed ID: 15796087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Bone disease in multiple myeloma and its mechanism].
    Abe M
    Clin Calcium; 2006 Apr; 16(4):565- 71. PubMed ID: 16582506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of the bone marrow microenvironment in multiple myeloma.
    Roodman GD
    J Bone Miner Res; 2002 Nov; 17(11):1921-5. PubMed ID: 12412796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CCR1 chemokines promote the chemotactic recruitment, RANKL development, and motility of osteoclasts and are induced by inflammatory cytokines in osteoblasts.
    Yu X; Huang Y; Collin-Osdoby P; Osdoby P
    J Bone Miner Res; 2004 Dec; 19(12):2065-77. PubMed ID: 15537451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significance of macrophage inflammatory protein-1 alpha (MIP-1alpha) in multiple myeloma.
    Terpos E; Politou M; Viniou N; Rahemtulla A
    Leuk Lymphoma; 2005 Dec; 46(12):1699-707. PubMed ID: 16263571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MIP-1alpha utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells.
    Oba Y; Lee JW; Ehrlich LA; Chung HY; Jelinek DF; Callander NS; Horuk R; Choi SJ; Roodman GD
    Exp Hematol; 2005 Mar; 33(3):272-8. PubMed ID: 15730850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of CCR1 and CCR5 in homing and growth of multiple myeloma and in the development of osteolytic lesions: a study in the 5TMM model.
    Menu E; De Leenheer E; De Raeve H; Coulton L; Imanishi T; Miyashita K; Van Valckenborgh E; Van Riet I; Van Camp B; Horuk R; Croucher P; Vanderkerken K
    Clin Exp Metastasis; 2006; 23(5-6):291-300. PubMed ID: 17086356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease.
    Giuliani N; Colla S; Sala R; Moroni M; Lazzaretti M; La Monica S; Bonomini S; Hojden M; Sammarelli G; Barillè S; Bataille R; Rizzoli V
    Blood; 2002 Dec; 100(13):4615-21. PubMed ID: 12393684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ability of myeloma cells to secrete macrophage inflammatory protein (MIP)-1alpha and MIP-1beta correlates with lytic bone lesions in patients with multiple myeloma.
    Hashimoto T; Abe M; Oshima T; Shibata H; Ozaki S; Inoue D; Matsumoto T
    Br J Haematol; 2004 Apr; 125(1):38-41. PubMed ID: 15015966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct stimulation of osteoclastogenesis by MIP-1alpha: evidence obtained from studies using RAW264 cell clone highly responsive to RANKL.
    Watanabe T; Kukita T; Kukita A; Wada N; Toh K; Nagata K; Nomiyama H; Iijima T
    J Endocrinol; 2004 Jan; 180(1):193-201. PubMed ID: 14709158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CCL9/MIP-1gamma and its receptor CCR1 are the major chemokine ligand/receptor species expressed by osteoclasts.
    Lean JM; Murphy C; Fuller K; Chambers TJ
    J Cell Biochem; 2002; 87(4):386-93. PubMed ID: 12397598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) correlate with the extent of bone disease and survival in patients with multiple myeloma.
    Terpos E; Politou M; Szydlo R; Goldman JM; Apperley JF; Rahemtulla A
    Br J Haematol; 2003 Oct; 123(1):106-9. PubMed ID: 14510950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Macrophage inflammatory protein-1alpha (MIP-1alpha) enhances a receptor activator of nuclear factor kappaB ligand (RANKL) expression in mouse bone marrow stromal cells and osteoblasts through MAPK and PI3K/Akt pathways.
    Tsubaki M; Kato C; Manno M; Ogaki M; Satou T; Itoh T; Kusunoki T; Tanimori Y; Fujiwara K; Matsuoka H; Nishida S
    Mol Cell Biochem; 2007 Oct; 304(1-2):53-60. PubMed ID: 17549607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Mechanisms for formation of myeloma bone disease].
    Yata K; Abe M; Matsumoto T
    Clin Calcium; 2008 Apr; 18(4):438-46. PubMed ID: 18379024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.